Bone Marrow Stem Cells

Duong, Minh; Ma, Yuting; Chiu, Ray Chu‐Jeng

doi:10.1007/978-1-62703-511-8_3

Cited by 3 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both TGF- β 1 and 5-AZA are common inducers that are used to induce the differentiation of BMMSCs into cardiomyocyte-like cells in vitro . However, 5-AZA can cause an imbalance and affect chromatin organization at the concentration that has an inducing effect, while TGF- β 1 revealed very low efficiency [ 10 , 11 ].…”

Section: Discussionmentioning

confidence: 99%

“…Experimental evidence clearly demonstrated that BMMSCs may differentiate into cardiomyocytes in vitro and in vivo and may be home to areas of ischemic injury following the administration of BMMSCs, to provide functional recovery [ 7 ]. Many studies have shown that 5-azacytidine (5-AZA) can induce BMMSCs to differentiate into cardiomyocytes [ 8 – 10 ]. It is well known that transforming growth factor- β 1 (TGF- β 1) can play a similar role in the cardiac differentiation process of BMMSCs [ 10 – 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…Many studies have shown that 5-azacytidine (5-AZA) can induce BMMSCs to differentiate into cardiomyocytes [ 8 – 10 ]. It is well known that transforming growth factor- β 1 (TGF- β 1) can play a similar role in the cardiac differentiation process of BMMSCs [ 10 – 12 ]. However, 5-AZA can affect cell survival after induction because of its obvious toxicity as an antineoplastic agent [ 10 ], while TGF- β 1 reveals very low efficiency [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…It is well known that transforming growth factor- β 1 (TGF- β 1) can play a similar role in the cardiac differentiation process of BMMSCs [ 10 – 12 ]. However, 5-AZA can affect cell survival after induction because of its obvious toxicity as an antineoplastic agent [ 10 ], while TGF- β 1 reveals very low efficiency [ 11 ]. One of the main challenges of cell therapy is to identify an induction method with a high differentiation rate and low cytotoxicity.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte‐Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor‐β1 and 5‐Azacytidine

Shi

Wen

et al. 2015

Stem Cells International

View full text Add to dashboard Cite

Bone marrow mesenchymal stem cells (BMMSCs) are used in cardiac tissue engineering for the regeneration of diseased hearts. We examined the differentiation of rat BMMSCs into cardiomyocyte-like cells when induced with a combined low dose treatment of transforming growth factor-β1 (TGF-β1) and 5-azacytidine (5-AZA). Results showed that cell proliferation in the combined low dose treatment group of TGF-β1 and 5-AZA was increased compared with the TGF-β1 group or the 5-AZA group. The cell apoptosis was relieved by combined TGF-β1 and 5-AZA treatment compared to 5-AZA treatment alone. The number of cells positive for myosin heavy chain, connexin-43, α-actin, and troponin I in the combined treatment group was higher than those observed in the TGF-β1 group or the 5-AZA group. Moreover, the combined low dose treatment group of TGF-β1 and 5-AZA reveals the strongest expression of troponin I, α-actin, and phosphorylated extracellular signal-regulated protein kinases 1 and 2 (p-ErK1/2) among the treatment groups. These results suggest that the combined low dose treatment of TGF-β1 and 5-AZA can improve the differentiation potential of rat BMMSCs into cardiomyocyte-like cells and alleviate cell damage effects in vitro. The mechanism that is involved in influencing differentiation may be associated with p-ErK1/2.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte‐Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor‐β1 and 5‐Azacytidine

Shi

Wen

et al. 2015

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…BMMSCs have been demonstrated to be multipotent and capable of differentiating into various mesodermal and ectodermal lineages. This capability suggests their potential application in therapeutic tissue repair procedures (Malgieri et al, ; Kagami et al, ; Duong et al, ; Frenette et al, ). Additionally, compared with DPSCs, BMMSCs are easier to obtain from autologous donors.…”

Section: Introductionmentioning

confidence: 99%

In vitro‐induced differentiation of bone marrow mesenchymal stem cells into melanocytes

Mei

Sun

et al. 2015

Cell Biology International

View full text Add to dashboard Cite

Large numbers of autogenous melanocytes (Mcs) are required when conducting studies on tissue engineering of skin and performing surgical treatment of depigmentation diseases. This study was conducted to explore the possibility of inducing differentiation of bone marrow mesenchymal stem cells (MSCs) into Mcs as a means of providing autogenous Mcs for purposes of tissue engineering and clinical treatment. MSCs were harvested from the bone marrows of black mice; and after six passages, hydrocortisone, insulin, transferrin and fibroblast growth factor were applied to induce their differentiation into Mcs. The morphological and ultrastructural characteristics of the newly differentiated cells were observed. The transcription and expression of multiple markers were examined using qRT-PCR, Western blot, and immunofluorescence analysis. Cell cycle phases and yields of Mcs were analyzed by flow cytometry. Following 120-180 days induction, differentiated cells were morphologically similar to Mcs, and mature melanosomes were observed. Multiple markers of Mcs, but not melanoma cells, were expressed by the differentiated cells. Most induced Mcs were in phase G1 or S, and yield of target cells was ∼80%. Mcs induced from bone marrow MSCs for periods of 120-180 days represent a potential source of autogenous Mcs.

show abstract

Triiodo-L-Thyronine Promotes the Maturation of Cardiomyocytes Derived From Rat Bone Marrow Mesenchymal Stem Cells

Shi

Wen³

et al. 2016

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Bone marrow mesenchymal stem cells (BMMSCs) can differentiate into cardiomyocytes and be used in cardiac tissue engineering for heart regeneration. However, the effective clinical application of cardiomyocytes derived from BMMSCs is limited because of their immature phenotype. The aim of this study was to investigate the potential of triiodo-L-thyronine (T3) to drive cardiomyocytes derived from BMMSCs to a more mature state. BMMSCs were divided into 3 groups: untreated controls, differentiated, and T3 treated. The differentiation potential was evaluated by immunofluorescence microscopy and flow cytometry. Data were represented as the numbers of cells positive for the troponin I (cTnI), α-actinin, GATA4, and the connexin-43 (Cx-43). The mRNA levels of these specific markers of cardiomyocytes were determined by quantitative real-time polymerase chain reaction. The levels of cardiomyocytes markers protein and octamer-binding transcription factor 4 (Oct-4) were determined by Western blot analyses. Our data demonstrate that T3 treatment leads to a significant increase in cells positive for cTnI, GATA4, Cx-43, and α-actinin. The mRNA and protein expression levels of these specific markers of cardiomyocytes were also increased after T3 treatment. At the same time, the protein expression level of Oct-4 was substantially downregulated in T3-treated cells. These results demonstrate that T3 treatment increases the differentiation of BMMSCs induced to cardiomyocytes and promotes their maturation.

show abstract

Bone Marrow Stem Cells

Cited by 3 publications

References 14 publications

Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte‐Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor‐β1 and 5‐Azacytidine

Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte‐Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor‐β1 and 5‐Azacytidine

In vitro‐induced differentiation of bone marrow mesenchymal stem cells into melanocytes

Triiodo-L-Thyronine Promotes the Maturation of Cardiomyocytes Derived From Rat Bone Marrow Mesenchymal Stem Cells

Contact Info

Product

Resources

About